Immuron Limited announced FY26 unaudited sales of AUD$7.7 million, up 6% year-over-year, driven by growth in Australia (+10%) and the USA (+7% AUD, +13% USD) for its Travelan® product. Australia's growth was attributed to increased digital marketing, same-store growth, and new retail placements, while US growth benefited from improved Amazon pre...

Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for IMM-529, its investigational polyclonal antibody treatment for Clostridioides difficile infection (CDI). The company has FDA approval for the IND application and is preparing for Phase 2 clinical trials in Australia. Based on market assessments, IMM-529 could gene...

Immuron Limited announced Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by growth in Australia (+15%), Canada (+82% quarter-over-quarter), and the USA (+1%). The company attributed growth to increased digital marketing, new retail partnerships, and brand awareness initiatives for its Travelan® product across all regions.

Immuron Limited reported H1 FY26 global sales of AUD$4.2 million with 5% growth and strong U.S. momentum (+17% YoY). The company raised AUD$7.3 million and announced a strategic reset focusing on partnerships to advance its Travelan® and IMM-529 clinical programs. IMM-124E is eligible for FDA end of Phase 2 meeting, while IMM-529 received FDA IN...

Immuron Limited receives a U.S. Department of Defense subaward to develop oral therapeutics targeting Campylobacter and Shigella, with plans to produce hyper-immune bovine colostrum products for pre-clinical evaluation and potential military use.